Asia Pacific NIPT Market Outlook 2018
Non-Invasive Prenatal Testing (NIPT) has catapulted growth in the molecular diagnostics market. In the US, where the test was initially launched, the market is expected to grow at a CAGR of 49% during 2013-2018. However, owing to a restrictive potential population base in USA, which is estimated at around 700,000, companies based in the region have been quick to expand beyond their geography and launch the tests in the EU and selective regions of Asia-Pacific (APAC). For RNCOS’ study, its experts have selected the APAC region since it represents a highly under penetrated market with immense potential for growth.
The APAC has almost one-third of the global population. According to RNCOS’ report “Asia Pacific NIPT Market Outlook 2018”, there are around 2 Million potential patients (high-risk age group) in the region, representing an over US$ 2 Billion worth potential market. The major market in this region lies in Japan, where the rapidly ageing population has created a huge, untapped potential market for the companies. China is another major region where two local players, BGI and Berry Genomics, are estimated to have collectively conducted around 100,000 tests in 2013 alone.
With the launch of a few NIPT tests, India represents a great opportunity for the growth of NIPT. The trend of pregnancies has witnessed a fundamental change in India in terms of the age of conceiving. Previously, the age group for pregnancy was usually 25 to 30 years. Now, it has increased to 28 to 35 years and above 35 years in some cases. This, therefore, augurs well for the growth of NIPT in India over the next few years. However, the growth can be marred by a lack of awareness of such tests and relatively lower affordability, with a major chunk of births taking place in the rural India.
RNCOS, in its report, covers an exhaustive analysis of the potential population for NIPT tests in the various regions. Different scenarios have also been explored in line with the regulatory environment in the different regions. Detailed description too has been provided of the current market scenario highlighting the currently available tests, business model followed by players, cost of their tests, number of tests accessioned by them, etc.
Besides, test volumes and markets till 2018 have been forecasted. These forecasts have been conducted on the basis of co-relation and judgmental analysis, which was carried out after carefully studying key factors, including rise in penetration, expansion in distributor network, rising popularity and awareness amongst consumers, regulatory scenario, and various other drivers and challenges.
Overall, the report presents optimum information and a transparent research outlook that highlights opportunities and potentials in the nascent APAC NIPT sector.
The APAC has almost one-third of the global population. According to RNCOS’ report “Asia Pacific NIPT Market Outlook 2018”, there are around 2 Million potential patients (high-risk age group) in the region, representing an over US$ 2 Billion worth potential market. The major market in this region lies in Japan, where the rapidly ageing population has created a huge, untapped potential market for the companies. China is another major region where two local players, BGI and Berry Genomics, are estimated to have collectively conducted around 100,000 tests in 2013 alone.
With the launch of a few NIPT tests, India represents a great opportunity for the growth of NIPT. The trend of pregnancies has witnessed a fundamental change in India in terms of the age of conceiving. Previously, the age group for pregnancy was usually 25 to 30 years. Now, it has increased to 28 to 35 years and above 35 years in some cases. This, therefore, augurs well for the growth of NIPT in India over the next few years. However, the growth can be marred by a lack of awareness of such tests and relatively lower affordability, with a major chunk of births taking place in the rural India.
RNCOS, in its report, covers an exhaustive analysis of the potential population for NIPT tests in the various regions. Different scenarios have also been explored in line with the regulatory environment in the different regions. Detailed description too has been provided of the current market scenario highlighting the currently available tests, business model followed by players, cost of their tests, number of tests accessioned by them, etc.
Besides, test volumes and markets till 2018 have been forecasted. These forecasts have been conducted on the basis of co-relation and judgmental analysis, which was carried out after carefully studying key factors, including rise in penetration, expansion in distributor network, rising popularity and awareness amongst consumers, regulatory scenario, and various other drivers and challenges.
Overall, the report presents optimum information and a transparent research outlook that highlights opportunities and potentials in the nascent APAC NIPT sector.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. INTRODUCTION
3.1 MaterniT21 PLUS
3.2 Verifi
3.3 Panorama
3.4 Harmony
3.5 NIFTY
3.6 Bambni
4. ASSOCIATION OF DOWN’S SYNDROME RISK TO FETUS WITH MOTHER’S AGE
5. ASIA-PACIFIC NIPT MARKET OUTLOOK TO 2018
5.1 Australia
5.1.1 Market Potential
5.1.2 Market Overview
5.1.3 Regulatory Scenario
5.2 China
5.2.1 Market Potential
5.2.2 Market Overview
5.2.3 Regulatory Scenario
5.3 Japan
5.3.1 Market Potential
5.3.2 Market Overview
5.3.3 Regulatory Scenario
5.4 India
5.4.1 Market Potential
5.4.2 Regulatory Scenario
2. RESEARCH METHODOLOGY
3. INTRODUCTION
3.1 MaterniT21 PLUS
3.2 Verifi
3.3 Panorama
3.4 Harmony
3.5 NIFTY
3.6 Bambni
4. ASSOCIATION OF DOWN’S SYNDROME RISK TO FETUS WITH MOTHER’S AGE
5. ASIA-PACIFIC NIPT MARKET OUTLOOK TO 2018
5.1 Australia
5.1.1 Market Potential
5.1.2 Market Overview
5.1.3 Regulatory Scenario
5.2 China
5.2.1 Market Potential
5.2.2 Market Overview
5.2.3 Regulatory Scenario
5.3 Japan
5.3.1 Market Potential
5.3.2 Market Overview
5.3.3 Regulatory Scenario
5.4 India
5.4.1 Market Potential
5.4.2 Regulatory Scenario
LIST OF FIGURES:
Figure 5-1: Australia - Number of Births (‘000), 2012-2018
Figure 5-2: Australia - Number of Births by Mother’s Risk of Down’s syndrome (%), 2013
Figure 5-3: Australia - Potential Market in Three Different Scenarios (US$), 2013
Figure 5-4: Australia - NIPT Market (Million US$), 2013-2018
Figure 5-5: Australia - NIPT Market (Volume ‘000), 2013-2018
Figure 5-6: China - Number of Births (Million), 2012-2018
Figure 5-7: China - Number of Births by Mother's Risk of Down's syndrome (%), 2013
Figure 5-8: China - Potential Market in Two Different Scenarios (US$), 2013
Figure 5-9: China - NIPT Market (Million US$), 2013-2018
Figure 5-10: China - NIPT Market (Volume ‘000), 2013-2018
Figure 5-11: Japan - Number of Births (‘000), 2012-2018
Figure 5-12: Japan - Number of Births by Mother’s Risk of Down’s syndrome (%), 2013
Figure 5-13: Japan - Potential Market in Two Different Scenarios (US$), 2013
Figure 5-14: Japan - NIPT Market (Million US$), 2013-2018
Figure 5-15: Japan - NIPT Market (Volume ‘00), 2013-2018
Figure 5-16: India - Number of Births (Million), 2012-2018
Figure 5-17: India - Number of Births by Mother’s Risk of Down’s syndrome (%), 2013
Figure 5-18: India - Potential Market in Two Different Scenarios (US$), 2013
Figure 5-1: Australia - Number of Births (‘000), 2012-2018
Figure 5-2: Australia - Number of Births by Mother’s Risk of Down’s syndrome (%), 2013
Figure 5-3: Australia - Potential Market in Three Different Scenarios (US$), 2013
Figure 5-4: Australia - NIPT Market (Million US$), 2013-2018
Figure 5-5: Australia - NIPT Market (Volume ‘000), 2013-2018
Figure 5-6: China - Number of Births (Million), 2012-2018
Figure 5-7: China - Number of Births by Mother's Risk of Down's syndrome (%), 2013
Figure 5-8: China - Potential Market in Two Different Scenarios (US$), 2013
Figure 5-9: China - NIPT Market (Million US$), 2013-2018
Figure 5-10: China - NIPT Market (Volume ‘000), 2013-2018
Figure 5-11: Japan - Number of Births (‘000), 2012-2018
Figure 5-12: Japan - Number of Births by Mother’s Risk of Down’s syndrome (%), 2013
Figure 5-13: Japan - Potential Market in Two Different Scenarios (US$), 2013
Figure 5-14: Japan - NIPT Market (Million US$), 2013-2018
Figure 5-15: Japan - NIPT Market (Volume ‘00), 2013-2018
Figure 5-16: India - Number of Births (Million), 2012-2018
Figure 5-17: India - Number of Births by Mother’s Risk of Down’s syndrome (%), 2013
Figure 5-18: India - Potential Market in Two Different Scenarios (US$), 2013
LIST OF TABLES:
Table 3-1: Comparison of Features of Key NIPT Tests in APAC NIPT Market
Table 3-2: MaterniT21 PLUS Test Validation Results
Table 3-3: Verifi Test Validation Results
Table 3-4: Panorma Test Validation Results
Table 3-5: Harmony Test Validation Results
Table 3-6: NIFTY Test - Summary of Phase I Clinical Trial
Table 3-7: NIFTY Test - Summary of Phase II Clinical Trial
Table 3-8: Bambni Test - Summary of Phase I Clinical Trial
Table 3-9: Bambni Test - Summary of Phase II Clinical Trial
Table 4-1: Risk of Down’s syndrome with Rise in Maternal Age
Table 5-1: Australia - Number of Births by Age of Mother (2012)
Table 5-2: Australia - Number of Births by Age of Mother (2013)
Table 5-3: Australia NIPT Market Landscape - Players; Australian Partner; Cost per Test
Table 5-4: China - Number of Births by Age of Mother (2012)
Table 5-5: China - Number of Births by Age of Mother (2013)
Table 5-6: China NIPT Market Landscape - Players; Cost per Test
Table 5-7: Japan - Number of Births by Age of Mother (2012)
Table 5-8: Japan - Number of Births by Age of Mother (2013)
Table 5-9: Japan NIPT Market Landscape - Player; Cost per Test
Table 5-10: India - Number of Births by Age of Mother (2000)
Table 5-11: India - India - Number of Births by Age of Mother (2013)
Table 3-1: Comparison of Features of Key NIPT Tests in APAC NIPT Market
Table 3-2: MaterniT21 PLUS Test Validation Results
Table 3-3: Verifi Test Validation Results
Table 3-4: Panorma Test Validation Results
Table 3-5: Harmony Test Validation Results
Table 3-6: NIFTY Test - Summary of Phase I Clinical Trial
Table 3-7: NIFTY Test - Summary of Phase II Clinical Trial
Table 3-8: Bambni Test - Summary of Phase I Clinical Trial
Table 3-9: Bambni Test - Summary of Phase II Clinical Trial
Table 4-1: Risk of Down’s syndrome with Rise in Maternal Age
Table 5-1: Australia - Number of Births by Age of Mother (2012)
Table 5-2: Australia - Number of Births by Age of Mother (2013)
Table 5-3: Australia NIPT Market Landscape - Players; Australian Partner; Cost per Test
Table 5-4: China - Number of Births by Age of Mother (2012)
Table 5-5: China - Number of Births by Age of Mother (2013)
Table 5-6: China NIPT Market Landscape - Players; Cost per Test
Table 5-7: Japan - Number of Births by Age of Mother (2012)
Table 5-8: Japan - Number of Births by Age of Mother (2013)
Table 5-9: Japan NIPT Market Landscape - Player; Cost per Test
Table 5-10: India - Number of Births by Age of Mother (2000)
Table 5-11: India - India - Number of Births by Age of Mother (2013)
